Meeting
2023 ASCO Genitourinary Cancers Symposium
Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.
Authors
Christopher Sweeney
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia
Christopher Sweeney , Ryon Graf , David Fabrizio , Kobe Yuen , Matthew J. Wongchenko , Pratyush Gupta , Priti Hegde , Geoffrey R. Oxnard , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT03016312
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr LBA249)
DOI
10.1200/JCO.2023.41.6_suppl.LBA249
Abstract #
LBA249
Poster Bd #
J10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christopher Sweeney
Poster
2017 ASCO Annual Meeting
A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Thomas Powles
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2023 ASCO Genitourinary Cancers Symposium
Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen